TSMHT
ASND icon

Thurston Springer Miller Herd & Titak’s Ascendis Pharma A/S ASND Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-14
Closed -$2.12K – 1571
2024
Q1 		$2.12K Buy
+14
New +$2K ﹤0.01% 141

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's ASND Position: Q2 2024 in Review

Thurston Springer Miller Herd & Titak sold out of Ascendis Pharma A/S (ASND) in Q2 2024, closing a stake of 14 shares — an estimated $2.12K sold.

Thurston Springer Miller Herd & Titak first reported a position in ASND in Q1 2024 and held it in 1 quarter. The position peaked at $2.12K in Q1 2024. 203 funds tracked by Wall St. Rank hold ASND as of Q2 2024.

  • Thurston Springer Miller Herd & Titak reported no remaining Ascendis Pharma A/S position as of Q2 2024 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 14 Ascendis Pharma A/S shares in Q2 2024, an estimated $2.12K.
  • Thurston Springer Miller Herd & Titak first reported a position in Ascendis Pharma A/S in Q1 2024 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Ascendis Pharma A/S position peaked at $2.12K in Q1 2024.
  • 203 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2024.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2024, filed 5 Jul 2024.